TRVITrevi Therapeutics, Inc.
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IP…
Industry Peers
Biotechnology| Headline | Source | Time |
|---|---|---|
Older | ||
 Trevi Therapeutics Q2 Earnings Call Highlights Trevi Therapeutics (NASDAQ:TRVI) said it began two clinical trials during the second quarter and plans to launch a third study in the third quarter as it advances nalbuphine ER, also known as Haduvio, for multiple chronic-cough indications. President and Chief Executive Officer Jennifer Good said t | ||
Trevi Therapeutics Inc (TRVI) (Q2 2026) Earnings Call Highlights: Advancing Phase 3 Pipeline ... Trevi Therapeutics Inc (TRVI) reports progress in IPF and RCC trials, backed by $319 million in funding and a competitive edge following a rival's program exit. | ||
 Trevi Therapeutics (TRVI) Soars as Haduvio Taps Into $15B Addressable Market Trevi Therapeutics grew its share prices by 9.85 percent on Friday to finish at $19.07 apiece, after management underscored strong clinical trial results from its treatment candidate for chronic cough. Speaking at a three-day conference in Europe, Trevi Therapeutics Inc (NASDAQ:TRVI) CEO Jennifer Good and Chief Development Officer James Cassella highlighted that the oral treatment […] | IInsider Monkey | |